drugset / Trial / NCT01469923

To Assess the Safety, Tolerability, Pharmacokinetics and Pharmakodynamics of AZD2820 After Multiple Ascending Doses

NCT01469923 ↗

Phase 1 Terminated 18 enrolled AstraZeneca
RandomizedParallel-groupSingle-blindBasic science

Summary

This is a randomised and single-blind, placebo-controlled study to investigate the safety, tolerabilty, pharmacokinetics and pharmacodynamics of repeated and ascending doses of AZD2820 to obese but otherwise healthy male subjects.

Timeline

Start
2012-03
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator AZD2820 Unknown — Subcutaneous

Indications